A citation-based method for searching scientific literature

Debra A Schaumberg, Robert J Glynn, Alicia J Jenkins, Timothy J Lyons, Nader Rifai, JoAnn E Manson, Paul M Ridker, David M Nathan. Circulation 2005
Times Cited: 78







List of co-cited articles
606 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
19


Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study.
Trevor J Orchard, Jon C Olson, John R Erbey, Katherine Williams, Kimberly Y-Z Forrest, Leslie Smithline Kinder, Demetrius Ellis, Dorothy J Becker. Diabetes Care 2003
319
14

Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.
David M Nathan, John Lachin, Patricia Cleary, Trevor Orchard, David J Brillon, Jye-Yu Backlund, Daniel H O'Leary, Saul Genuth. N Engl J Med 2003
596
10

Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes.
Rieko Hayaishi-Okano, Yoshimitsu Yamasaki, Naoto Katakami, Kentaro Ohtoshi, Shin-Ichi Gorogawa, Akio Kuroda, Munehide Matsuhisa, Keisuke Kosugi, Norikiyo Nishikawa, Yoshitaka Kajimoto,[...]. Diabetes Care 2002
86
10


Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
P M Ridker, M Cushman, M J Stampfer, R P Tracy, C H Hennekens. N Engl J Med 1997
8

Can clinical factors estimate insulin resistance in type 1 diabetes?
K V Williams, J R Erbey, D Becker, S Arslanian, T J Orchard. Diabetes 2000
281
8

Acute-phase proteins among patients with type 1 diabetes.
M B Gomes, L J Piccirillo, V G Nogueira, H J Matos. Diabetes Metab 2003
44
13

Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study.
Miranda T Schram, Nish Chaturvedi, Casper Schalkwijk, Francesco Giorgino, Pertti Ebeling, John H Fuller, Coen D Stehouwer. Diabetes Care 2003
169
7

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.
A D Pradhan, J E Manson, N Rifai, J E Buring, P M Ridker. JAMA 2001
7

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A Dormandy, Bernard Charbonnel, David J A Eckland, Erland Erdmann, Massimo Massi-Benedetti, Ian K Moules, Allan M Skene, Meng H Tan, Pierre J Lefèbvre, Gordon D Murray,[...]. Lancet 2005
7

High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database.
Sabita S Soedamah-Muthu, John H Fuller, Henrietta E Mulnier, Veena S Raleigh, Ross A Lawrenson, Helen M Colhoun. Diabetes Care 2006
236
7



Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes.
Sridevi Devaraj, Nicole Glaser, Steve Griffen, Janice Wang-Polagruto, Eric Miguelino, Ishwarlal Jialal. Diabetes 2006
216
7

Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients.
M Saraheimo, A-M Teppo, C Forsblom, J Fagerudd, P-H Groop. Diabetologia 2003
177
7


Determinants of raised C-reactive protein concentration in type 1 diabetes.
E S Kilpatrick, B G Keevil, C Jagger, R J Spooner, M Small. QJM 2000
33
15

The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus.
S P Laing, A J Swerdlow, S D Slater, J L Botha, A C Burden, N R Waugh, A W Smith, R D Hill, P J Bingley, C C Patterson,[...]. Diabet Med 1999
234
6

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
John Danesh, Jeremy G Wheeler, Gideon M Hirschfield, Shinichi Eda, Gudny Eiriksdottir, Ann Rumley, Gordon D O Lowe, Mark B Pepys, Vilmundur Gudnason. N Engl J Med 2004
6



CRP and IL-6 concentrations are associated with poor glycemic control despite preserved beta-cell function during the first year after diagnosis of type 1 diabetes.
Anna Schölin, Agneta Siegbahn, Lars Lind, Christian Berne, Göran Sundkvist, Elisabeth Björk, F Anders Karlsson. Diabetes Metab Res Rev 2004
25
20


Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes.
Jon C Olson, John R Erbey, Kimberly Y Z Forrest, Katherine Williams, Dorothy J Becker, Trevor J Orchard. Metabolism 2002
49
10



Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.
Jonathan Q Purnell, Raj K Dev, Michael W Steffes, Patricia A Cleary, Jerry P Palmer, Irl B Hirsch, John E Hokanson, John D Brunzell. Diabetes 2003
59
8


Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
6

Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial.
Julie Lin, Robert J Glynn, Nader Rifai, JoAnn E Manson, Paul M Ridker, David M Nathan, Debra A Schaumberg. Diabetes Care 2008
74
6

Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study.
Janet K Snell-Bergeon, Nancy A West, Elizabeth J Mayer-Davis, Angela D Liese, Santica M Marcovina, Ralph B D'Agostino, Richard F Hamman, Dana Dabelea. J Clin Endocrinol Metab 2010
81
6

Inflammation and atherosclerosis.
Peter Libby, Paul M Ridker, Attilio Maseri. Circulation 2002
5

Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus.
A S Krolewski, E J Kosinski, J H Warram, O S Leland, E J Busick, A C Asmal, L I Rand, A R Christlieb, R F Bradley, C R Kahn. Am J Cardiol 1987
523
5


Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Steven M Haffner, Andrew S Greenberg, Wayde M Weston, Hongzi Chen, Ken Williams, Martin I Freed. Circulation 2002
702
5

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I Mackness, Valentine Charlton-Menys, John H Fuller. Lancet 2004
5

Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia.
Alicia J Jenkins, Timothy J Lyons, Deyi Zheng, James D Otvos, Daniel T Lackland, Daniel McGee, W Timothy Garvey, Richard L Klein. Diabetes Care 2003
81
5

Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels.
Troels Krarup Hansen, Steffen Thiel, Pieter Jozef Wouters, Jens Sandahl Christiansen, Greet Van den Berghe. J Clin Endocrinol Metab 2003
346
5

C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification.
Helen M Colhoun, Casper Schalkwijk, Michael B Rubens, Coen D A Stehouwer. Diabetes Care 2002
51
7

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.
Thomas A Pearson, George A Mensah, R Wayne Alexander, Jeffrey L Anderson, Richard O Cannon, Michael Criqui, Yazid Y Fadl, Stephen P Fortmann, Yuling Hong, Gary L Myers,[...]. Circulation 2003
5

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
Andreas Pfützner, Nikolaus Marx, Georg Lübben, Matthias Langenfeld, Daniel Walcher, Thomas Konrad, Thomas Forst. J Am Coll Cardiol 2005
235
5


The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results.
J S Dorman, R E Laporte, L H Kuller, K J Cruickshanks, T J Orchard, D K Wagener, D J Becker, D E Cavender, A L Drash. Diabetes 1984
317
5

Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes.
S P Laing, A J Swerdlow, S D Slater, A C Burden, A Morris, N R Waugh, W Gatling, P J Bingley, C C Patterson. Diabetologia 2003
474
5

Cardiovascular morbidity and mortality associated with the metabolic syndrome.
B Isomaa, P Almgren, T Tuomi, B Forsén, K Lahti, M Nissén, M R Taskinen, L Groop. Diabetes Care 2001
5

Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes.
Shalamar D Sibley, Jerry P Palmer, Irl B Hirsch, John D Brunzell. J Clin Endocrinol Metab 2003
47
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.